Outlook Therapeutics Gestione

Criteri Gestione verificati 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Bob Jahr

Amministratore delegato

US$1.7m

Compenso totale

Percentuale dello stipendio del CEO	8.61%
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	3.4yrs
Durata media del Consiglio di amministrazione	7.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Bob Jahr rispetto agli utili di Outlook Therapeutics?
Data	Compenso totale	Stipendio	Utili della società
Mar 31 2026	n/a	n/a	-US$61m
Dec 31 2025	n/a	n/a	-US$103m
Sep 30 2025	US$2m	US$150k	-US$62m

Compensazione vs Mercato: La retribuzione totale di Bob ($USD 1.74M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 738.19K ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Bob con le performance aziendali.

AMMINISTRATORE DELEGATO

Bob Jahr (53 yo)

less than a year

Mandato

US$1,741,757

Compensazione

Mr. Robert Charles Jahr, also known as Bob, is President, CEO & Director of Outlook Therapeutics, Inc. from July 1, 2025. From September 2018 to April 2020, he served as Vice President Head of US Payer Val...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Robert Jahr	President	less than a year	US$1.74m	Nessun dato
Lawrence Kenyon	EVP, CFO	10.8yrs	US$476.17k	0.0049% € 8.1k
Joel Prieve	Senior Vice President of Licensing and M&A	4.3yrs	Nessun dato	Nessun dato
Surendra Sharma	Senior Vice President of Medical Affairs	3.4yrs	Nessun dato	Nessun dato
Jennifer Kissner	Senior Vice President of Clinical Development & Regulatory Affairs	no data	Nessun dato	Nessun dato
Jedd Comiskey	Senior VP - Head of Europe	2.6yrs	Nessun dato	Nessun dato

3.4yrs

Durata media

Gestione esperta: Il team dirigenziale di 41O è considerato esperto (durata media dell'incarico 3.4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Robert Jahr	President	less than a year	US$1.74m	Nessun dato
Lawrence Kenyon	EVP, CFO	7.8yrs	US$476.17k	0.0049% € 8.1k
Kurt Hilzinger	Independent Director	10.5yrs	US$842.00k	0.35% € 578.7k
Ralph Thurman	Lead Independent Director	8.2yrs	US$836.50k	0.0046% € 7.6k
Julian Gangolli	Independent Non-Employee Director	6.2yrs	US$690.50k	0% € 0
Gerd Auffarth	Independent Non-Employee Director	6.2yrs	US$458.00k	0% € 0
Faisal Sukhtian	Independent Chairman of the Board	8.8yrs	US$1.00m	0.10% € 171.5k
Yezan Haddadin	Independent Director	8.7yrs	US$974.00k	0.055% € 90.4k
Andong Huang	Independent Director	6yrs	US$425.00k	0% € 0

7.8yrs

Durata media

60yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 41O sono considerati esperti (durata media dell'incarico 7.8 anni).

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/06/17 23:29
Prezzo dell'azione a fine giornata	2026/06/17 00:00
Utili	2026/03/31
Utili annuali	2025/09/30

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Outlook Therapeutics, Inc. è coperta da 9 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Edward Woo	Ascendiant Capital Markets LLC
Brian Kemp Dolliver	Brookline Capital Markets
Kumaraguru Raja	Brookline Capital Markets

Outlook Therapeutics Gestione

Criteri Gestione verificati 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Independent Director recently bought €152k worth of stock

Insufficient new directors

Outlook Therapeutics, Inc. Announces Resignation of Dr. Julia Haller from the Board and Member of the Nominating and Corporate Governance Committee, Effective March 11, 2026

Outlook Therapeutics, Inc., Annual General Meeting, Mar 10, 2026

Insufficient new directors

Outlook Therapeutics, Inc. Announces Chief Executive Officer Changes

Recent updates

Outlook Therapeutics, Inc. Announces FDA Acceptance Of Resubmitted Biologics License Application For ONS-5010/LYTENAVA (Bevacizumab-Vikg) As A Treatment For Wet AMD

Independent Director recently bought €152k worth of stock

Outlook Therapeutics, Inc. Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process For ONS-5010/LYTENAVA (Bevacizumab-Vikg) And Plans To Resubmit BLA To FDA In June 2026

Insufficient new directors

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering.

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

Outlook Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Outlook Therapeutics Inc. Announces FDA Accepts Formal Dispute Resolution Request for ONS-5010/LYTENAVA (Bevacizumab-Vikg)

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

Outlook Therapeutics, Inc. has filed a Follow-on Equity Offering.

Outlook Therapeutics, Inc. announced that it has received $18.36 million in funding from Atlas Sciences, LLC

Outlook Therapeutics, Inc. Announces Resignation of Dr. Julia Haller from the Board and Member of the Nominating and Corporate Governance Committee, Effective March 11, 2026

Outlook Therapeutics Provides Update Following Type A Meeting With FDA Regarding ONS-5010/LYTENAVA (Bevacizumab-Vikg)

Outlook Therapeutics, Inc. Receives Notice of Potential Delisting Due to Low Stock Price on Nasdaq

Outlook Therapeutics, Inc. Submits Type A Meeting Request to FDA Following Complete Response Letter

Outlook Therapeutics, Inc., Annual General Meeting, Mar 10, 2026

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of Ons-5010/Lytenava™ (Bevacizumab-Vikg) for the Treatment of Wet Amd

Insufficient new directors

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. Re-Submits Biologics License Application for ONS-5010

Outlook Therapeutics, Inc. Announces Type A Meeting with the U.S. Food and Drug Administration Resubmission for Ons-5010

Outlook Therapeutics, Inc. Provides Regulatory Update on U.S. Food and Drug Administration Review of Ons-5010/Lytenava™? (Bevacizumab-Vikg) for the Treatment of Wet Amd

Outlook Therapeutics, Inc. Announces Chief Executive Officer Changes

Outlook Therapeutics, Inc.(NasdaqCM:OTLK) dropped from Russell 2000 Index

Outlook Therapeutics®? Announces Smc Recommendation of Lytenava™ (Bevacizumab Grapa) for the Treatment of Wet Amd

Outlook Therapeutics, Inc. Announces Commercial Launch of LYTENAVA (bevacizumab G gamma) in Germany and the UK for the Treatment of Wet AMD

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $13 million.

Outlook Therapeutics, Inc. has filed a Follow-on Equity Offering.

Outlook Therapeutics, Inc. Announces U.S. Food and Drug Administration Resubmission of ONS-5010 Biologics License Application

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics, Inc., Annual General Meeting, Mar 11, 2025

Outlook Therapeutics, Inc. Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Outlook Therapeutics Announces Presentation of Efficacy and Safety Results from Norse Eight Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Outlook Therapeutics, Inc. Announces Complete Twelve Week Efficacy and Safety Results of Northeast EIGHT Clinical Trial

Outlook Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt

Outlook Therapeutics, Inc. Streamlines Operations

Outlook Therapeutics, Inc. Announces Chief Executive Officer Changes

Outlook Therapeutics, Inc Announces Resignation of Russell Trenary as President

Outlook Therapeutics, Inc. Announces Preliminary Topline Results of Norse Eight Clinical Trial

Forecast to breakeven in 2027

Outlook Therapeutics Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

New major risk - Financial position

Outlook Therapeutics, Inc. to Report Q3, 2024 Results on Aug 14, 2024

Insufficient new directors

Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. to Report Q2, 2024 Results on May 16, 2024

Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC

Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

New major risk - Shareholder dilution

Outlook Therapeutics, Inc. announced that it has received $59.999961 million in funding from a group of investors

Outlook Therapeutics Announces Effective Date for 1-For-20 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

No longer forecast to breakeven

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Doses First Subject in Norse Eight

Outlook Therapeutics Receives FDA Agreement under Special Protocol Assessment for 90 Day Non-Inferiority Study, NORSE EIGHT

Outlook Therapeutics, Inc. announced that it expects to receive $65 million in funding from a group of investors

Forecast breakeven date pushed back to 2026

Outlook Therapeutics, Inc. Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010

Outlook Therapeutics, Inc. Announces Strategic Organizational Realignment

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Outlook Therapeutics, Inc. Provides Update on Type A Meetings with FDA

Outlook Therapeutics Receives Non-Compliance Notice from Nasdaq

Outlook Therapeutics, Inc. Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD

New major risk - Negative shareholders equity

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $16.927904 million.

Forecast breakeven date moved forward to 2024